Gilead Sciences Completes $4.3 Billion Cymabay Acquisition-May 2024-www.financetom.com

Gilead Sciences Completes $4.3 Billion Cymabay Acquisition

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Gilead Sciences Completes $4.3 Billion Cymabay Acquisition

Mar 22, 2024 7:24 AM

09:56 AM EDT, 03/22/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday it has completed its $4.3 billion acquisition of CymaBay Therapeutics ( CBAY ).

The company said CymaBay's lead product candidate for primary biliary cholangitis, seladelpar, 'complements' its existing liver portfolio.

Price: 72.95, Change: -0.14, Percent Change: -0.19

Previous page： Oxford Lane Capital's Management Estimates May Net Asset Value of Up to $5.12 Next page： Oddity Tech's Board Approves $150 Million Stock Buyback Plan, Revises Q2 Outlook

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Oxford Lane Capital's Management Estimates May Net Asset Value of Up to $5.12

Jun 7, 2024

08:37 AM EDT, 06/07/2024 (MT Newswires) -- Oxford Lane Capital ( OXLC ) said Friday its management's unaudited estimated net asset value per share of its common stock is between $5.02 and $5.12 as of May 31. The company said the estimate was not approved by its board. The company added it had 266.3 million shares of its common stock...

Oddity Tech's Board Approves $150 Million Stock Buyback Plan, Revises Q2 Outlook

Jun 7, 2024

08:36 AM EDT, 06/07/2024 (MT Newswires) -- Oddity Tech ( ODD ) said Friday its board has approved a stock buyback program of up to $150 million of the company's class A ordinary shares. The program will expire on June 30, 2027, the company said. With the approval of the repurchase program, Oddity said it now expects Q2 adjusted earnings...

Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program

Jun 7, 2024

08:33 AM EDT, 06/07/2024 (MT Newswires) -- Plus Therapeutics ( PSTV ) said Friday it received notice of a $3.3 million advance payment from the Cancer Prevention & Research Institute of Texas, or CPRIT, as part of a $17.6 million grant awarded in September 2022. The company said the funding will support the leptomeningeal cancer radiotherapeutic development program and CNSide...

Kia to recall over 460,000 U.S. vehicles due to fire risks

Jun 7, 2024

June 7 (Reuters) - Kia America is recalling 462,869 Telluride vehicles in the U.S. due to a fire risk from overheated front power seat motor, the U.S. National Highway Traffic Safety Administration said on Friday. ...